A Double-blind, Randomized, Sham-controlled Study of Cranial Electrotherapy Stimulation as an Add-on Treatment for Tic Disorders in Children and Adolescents(SCATT)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Tic Disorder, Childhood
- Sponsor
- Xijing Hospital
- Enrollment
- 100
- Primary Endpoint
- Changes in Yale Global Tic Severity Scale (YGTSS) score
- Last Updated
- 7 years ago
Overview
Brief Summary
Tic disorders is recognized as a neuropsychiatric disease. The treatments of tic disorders include drug therapy, psychotherapy and physical therapy. As a non-invasive therapy, cranial electrotherapy stimulation(CES) is approved to have few side effects and applied in various areas, especially in psychiatric diseases. However, up to now there have been no results about the effects of CES in the treatment of tic disorders.The investigators hope CES could offer a useful approach for treating tic disorders.
Detailed Description
The investigators will conduct a randomized, double-blind, sham-controlled trial to determine the efficacy of CES as an add-on treatment for tic disorders (SCATT). The study will be conducted at an outpatient, single-center academic setting. A total of 100 patients aged 6 to 17 years with tic disorders and lack of clinical response to 4 weeks' pharmacotherapy will be enrolled. Patients will be randomly into 2 groups and given 4 weeks' treatment, including 40 daily 30-minute sessions of active CES(500μA\~2mA) or sham CES(lower than 100μA) on weekdays. Change in Yale Global Tic Severity Scale (YGTSS) is considered to be the primary outcome. The secondary outcome is the changes in Clinical Global Impression (CGI) and Hamilton Anxiety Scale (HAMA). Assessments will be performed at baseline, week 2, week 4 and week 8. Adverse events(AE) will be also evaluated.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Aged 6-17 years old
- •Diagnosed with TD, according to Intentional Classification of Diseases (ICD-10) criteria, currently in a phase of exacerbation.
- •Presented to be lack of response to medication after 4 weeks of treatment
Exclusion Criteria
- •Physical illnesses, such as cholera, hepatolenticular degeneration, myoclonic epilepsy, drug-induced extrapyramidal symptoms and organic diseases
- •Substance dependence and abuse
- •Severe psychiatric disease, such as depression, bipolar disorder, schizophrenic disease,
- •Risk for suicide or attempted suicide
- •Researchers think that the patient is not suitable for the study
Outcomes
Primary Outcomes
Changes in Yale Global Tic Severity Scale (YGTSS) score
Time Frame: 8 weeks
Change in Yale Global Tic Severity Scale (YGTSS) at baseline and week 2, 4, 8. The YGTSS is applied by means of a semistructured interview with multiple informants (generally, the parents) who assess the child's tics over a period of at least one week.
Secondary Outcomes
- Changes in Clinical Global Impression (CGI) score(8 weeks)
- adverse effects(8 weeks)
- Changes in The Hamilton Rating Scale for Anxiety (HAM-A) score(8 weeks)